The authors of the study have suggested that once-weekly insulin therapy would be easier for patients with type-2 diabetes than taking daily insulin injections especially in patients who are still learning about how to use insulin injections.
The study was published in New England Journal of Medicine
There is an increasing incidence of type-2 diabetes and related complications due to poor blood sugar control. The treatment for diabetes still is less than ideal even with introduction of recombinant insulin, adjunctive therapy, and real time glucose monitoring.
In patients whom the oral agents are ineffective, newer therapies and basal insulin dosing are required. Hence researchers Rosenstock and colleagues have tried to simplify basal insulin therapy in patients with type-2 diabetes with ultra-long acting basal insulin called icodec which can be administered once in a week.
The researchers compared weekly insulin icodec with daily insulin glargine U100 in clinical trial. The results of this study were that icodec was associated with no major adverse effects and was as effective as glargine in lowering blood sugar levels.
The incidence of hypoglycemia was slightly higher with icodec but less aggressive dose adjustment can help reduce the risk of hypoglycemia. Hypoglycemia is decrease in blood sugar and the symptoms include confusion, anxiety, palpitations, shakiness.
There is an increasing number of treatment options for patients with type-2 diabetes hence the particular participants which were included in the trial might not represent the typical patient with diabetes. Therefore further studies are needed to determine how once-weekly insulin can be incorporated in the standard of treatment algorithms.
The inability to vary the dose poses a problem for patients who are trying to incorporate exercise into their care regimen.
Patients with type 1 diabetes (destruction of insulin producing cell) can benefit from less frequent administration of insulin. However these patients need the ability to adjust the doses of long and short acting insulin.
Despite the concerns, this trial represents a new drug which can be added for lowering blood sugar. Further studies are required to understand the group of patients which will benefit the most from this study.